For informational purposes only — not investment advice

← Back to signals

CTY

INSIDER BUY

City Therapeutics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
2.3d
as of 2026-10-30

News Summary

Positive

City Therapeutics successfully closed a $230M IPO in mid-October 2026 and initiated its first Phase 1 trial for CITY-RBP4 (Stargardt disease) in November, establishing itself as a newly public RNAi-focused biotech. Analyst coverage initiation has been broadly bullish with average 12-month price target of $33, though the stock has traded below IPO pricing despite positive momentum, reflecting typical post-IPO volatility and the inherent risk profile of early-stage clinical programs.

Red flags

  • •Early-stage biotech with no approved products or clinical data yet — all value is speculative
  • •Stock trading below IPO price (~$18–19 range) despite bullish analyst initiations suggests market skepticism or profit-taking
  • •Limited public operating history; no earnings reports or revenue to evaluate financial performance
  • •Single Phase 1 program disclosed; pipeline concentration risk if lead candidates face clinical setbacks

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
ARCH Venture Partners XII, LLC—BUY170K$18.00$3.06M2026-10-19↗
NELSEN ROBERT—BUY170K$18.00$3.06M2026-10-19↗

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Viking GlobalSC 13GNEW7.0%
-5.3% vs SPY
-11.7% abs
2026-10-26↗